Javascript must be enabled to continue!
Probable Vancomycin-Induced Neutropenia
View through CrossRef
OBJECTIVE To report a case of vancomycin-induced neutropenia and provide a review of the literature. CASE SUMMARY A 64-year-old white man was treated with intravenous vancomycin 1.5 g/day for finger osteomyelitis. He developed neutropenia after 21 days of vancomycin therapy. The absolute neutrophil count reached a nadir of 418 cells/mm3 during vancomycin use and returned to normal 7 days after its discontinuation. The eosinophil count was also elevated during the neutropenic episode and probably related to vancomycin. Based on the Naranjo probability scale, the reaction was probably related to vancomycin use. DISCUSSION Articles describing cases of vancomycin-induced neutropenia were identified. All patients developed neutropenia as a result of vancomycin therapy 12 days. Neutrophil counts generally increased following discontinuation of vancomycin. One article reported successful resolution of neutropenia and infection by switching the patient's therapy to the structurally related antibiotic agent teicoplanin. Other patients were continued on vancomycin therapy, and neutropenia was treated with moderate to good success with filgrastim. Rechallenge was not generally attempted. The mechanism of neutropenia caused by vancomycin is unclear, but appears to be immune-mediated. CONCLUSIONS Vancomycin therapy should not be prolonged unless absolutely necessary, and therapy should be reserved for patients with clear indications for the drug, such as infections due to gram-positive organisms resistant to other therapies. Patients should have periodic assessment of white blood cell and neutrophil counts with consideration to discontinue vancomycin if neutropenia develops.
Title: Probable Vancomycin-Induced Neutropenia
Description:
OBJECTIVE To report a case of vancomycin-induced neutropenia and provide a review of the literature.
CASE SUMMARY A 64-year-old white man was treated with intravenous vancomycin 1.
5 g/day for finger osteomyelitis.
He developed neutropenia after 21 days of vancomycin therapy.
The absolute neutrophil count reached a nadir of 418 cells/mm3 during vancomycin use and returned to normal 7 days after its discontinuation.
The eosinophil count was also elevated during the neutropenic episode and probably related to vancomycin.
Based on the Naranjo probability scale, the reaction was probably related to vancomycin use.
DISCUSSION Articles describing cases of vancomycin-induced neutropenia were identified.
All patients developed neutropenia as a result of vancomycin therapy 12 days.
Neutrophil counts generally increased following discontinuation of vancomycin.
One article reported successful resolution of neutropenia and infection by switching the patient's therapy to the structurally related antibiotic agent teicoplanin.
Other patients were continued on vancomycin therapy, and neutropenia was treated with moderate to good success with filgrastim.
Rechallenge was not generally attempted.
The mechanism of neutropenia caused by vancomycin is unclear, but appears to be immune-mediated.
CONCLUSIONS Vancomycin therapy should not be prolonged unless absolutely necessary, and therapy should be reserved for patients with clear indications for the drug, such as infections due to gram-positive organisms resistant to other therapies.
Patients should have periodic assessment of white blood cell and neutrophil counts with consideration to discontinue vancomycin if neutropenia develops.
Related Results
Incidence, Management and Predictors of Chemotherapy-Induced Neutropenia among Adult Solid Cancer Patients at the University of Gondar Comprehensive and Specialized Hospital: A Retrospective Follow-up Study
Incidence, Management and Predictors of Chemotherapy-Induced Neutropenia among Adult Solid Cancer Patients at the University of Gondar Comprehensive and Specialized Hospital: A Retrospective Follow-up Study
Abstract
Background
chemotherapy-induced neutropenia is the most well-known oncologic emergencies and the most common hematologic toxicity of chemotherapy. A few studies h...
Immune-Mediated Thrombocytopenia in Patients Treated with Vancomycin.
Immune-Mediated Thrombocytopenia in Patients Treated with Vancomycin.
Abstract
Numerous drugs are known to cause immune thrombocytopenia (TP) mediated by antibodies (abs) that bind to platelets only when the sensitizing drug is present...
The prevalence of neutropenia in chemotherapy cancer patients at a provincial hospital, Thailand
The prevalence of neutropenia in chemotherapy cancer patients at a provincial hospital, Thailand
Abstract
Introduction
Cancer patients with neutropenia (<1500 cell/mm3 absolute neutrophil count [ANC]) are at high risk ...
P-1977. Adverse Event Profile of Vancomycin vs. Linezolid in Real-World Reports: A Disproportionality Analysis from the AERS Database
P-1977. Adverse Event Profile of Vancomycin vs. Linezolid in Real-World Reports: A Disproportionality Analysis from the AERS Database
Abstract
Background
Vancomycin and linezolid are critical agents in the treatment of multidrug-resistant gram-positive in...
Home monitoring of neutrophil counts by patients with cyclic and congenital neutropenia
Home monitoring of neutrophil counts by patients with cyclic and congenital neutropenia
Abstract
Background: Currently most blood cell counts are performed at clinical laboratories which is time-consuming, co...
598. Area under the curve-guided vancomycin monitoring and risk of nephrotoxicity in non-Staphylococcus aureus infections: A case-control study
598. Area under the curve-guided vancomycin monitoring and risk of nephrotoxicity in non-Staphylococcus aureus infections: A case-control study
Abstract
Background
Area under the curve (AUC)-guided monitoring of vancomycin for the treatment of Staphylococcus aureus (SA) i...
The Impact of Early Achievement of Therapeutic Levels of Vancomycin in Critically ill Patients with Confirmed Gram-positive Infection: A Retrospective Cohort Study
The Impact of Early Achievement of Therapeutic Levels of Vancomycin in Critically ill Patients with Confirmed Gram-positive Infection: A Retrospective Cohort Study
Abstract
Background: Vancomycin is a commonly used antibiotic in critically ill patients for various indications. Critical illness imposes pharmacokinetic-pharmacodynamics ...
The impact of early target attainment of vancomycin in critically ill patients with confirmed Gram-positive infection: A retrospective cohort study
The impact of early target attainment of vancomycin in critically ill patients with confirmed Gram-positive infection: A retrospective cohort study
Abstract
Background
Vancomycin is a commonly used antibiotic in critically ill patients for various indications. Critical illness imposes pharmacoki...

